Company Profile
Gylden Pharma Limited
09955881•Private Limited With Share Capital
Get Full Access
18/01/2016
10 years
7
36
72110
moderate risk
Company Overview
Registration, classification & business activity
Gylden Pharma Limited (09955881) is a private limited with share capital incorporated on 18/01/2016 (10 years old) and registered in abingdon, OX136BH. The company operates under SIC code 72110 - research and experimental development on biotechnology.
Emergex, a uk-based biotechnology company headquartered in abingdon, uk, is pioneering the development of set-point vaccines to address some of the world's most immediate health threats such as dengue fever, zika, ebola, pandemic flu and serious intra-cellular bacterial infections. these set-point v...
Financial Overview
£1.94M
£5.28M
£-3.34M
£2.00M
£294.4K
Key Metrics
36
Employees
7
Directors
139
Shareholders
3
Patents
Board of Directors
Charges
6
Registered
5
Outstanding
0
Part Satisfied
1
Satisfied
Innovate Grants
This company received a grant of £970402.0 for Generation Of A Clinical Universal Flu Vaccine Candidate. The project started on 01/05/2018 and ended on 30/04/2020.
This company received a grant of £490525.0 for Development Of A Cd8 T-Cell Priming Vaccine Against Chikungunya Virus. The project started on 01/04/2022 and ended on 31/03/2023.
+1 more grants available
Import / Export
Risk Assessment
moderate risk
International Score
Future Factor
fair
Performance Rating